Investors Asset Management of Georgia’s Jazz Pharmaceuticals JAZZ Stock Holding History

Investors Asset Management of Georgia’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-150	Closed	-$20K	–	354
2022 Q3	$20K	Hold	150	–	–	0.01%	400
2022 Q2	$23K	Buy	+150	New	+$23.1K	0.01%	327

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Investors Asset Management of Georgia's JAZZ Position: Q4 2022 in Review

Investors Asset Management of Georgia sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2022, closing a stake of 150 shares — an estimated $20K sold.

Investors Asset Management of Georgia first reported a position in JAZZ in Q2 2022 and held it in 2 quarters. The position peaked at $23K in Q2 2022. 485 funds tracked by Wall St. Rank hold JAZZ as of Q4 2022.

Investors Asset Management of Georgia reported no remaining Jazz Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Investors Asset Management of Georgia sold 150 Jazz Pharmaceuticals shares in Q4 2022, an estimated $20K.
Investors Asset Management of Georgia first reported a position in Jazz Pharmaceuticals in Q2 2022 and held it in 2 quarters.
Investors Asset Management of Georgia's Jazz Pharmaceuticals position peaked at $23K in Q2 2022.
485 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2022.

Based on Investors Asset Management of Georgia's 13F filing for Q4 2022, filed 2 Feb 2023.